Video: Every Case Tells a Story| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • QA/QI
    • Technology
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Diclofenac Patch, Piroxicam Most Effective Topical NSAIDs for Osteoarthritis

Reuters Staff  |  February 28, 2018

NEW YORK (Reuters Health)—Diclofenac patches appear to be the most effective topical nonsteroidal anti-inflammatory drug (NSAID) for osteoarthritis (OA), according to a new systematic review and network meta-analysis.

“Topical NSAIDs were effective and safe for OA,” Dr. Weiya Zhang of the University of Nottingham and City Hospital in the UK and colleagues write. “However, confirmation of the cardiovascular safety of topical NSAIDs still warrants further observational study.”

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

Topical NSAIDs may reduce the risk of gastrointestinal and cardiovascular side effects associated with systemic NSAID treatment, Dr. Zhang and colleagues note in the British Journal of Sports Medicine, online February 7. However, several types of adverse effects (AEs) have been reported with topical NSAIDs as well, they add.

They identified 43 studies, including 36 randomized controlled trials in 7,900 OA patients and seven observational studies in more than 218,000 people. Pain relief was superior with topical NSAIDs overall compared to placebo, while the medications also were superior for improving function in OA patients.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

Using a network meta-analysis, the authors were able to estimate the effect of 11 different topical NSAIDs compared with placebo. Diclofenac was most likely to be the best treatment in terms of pain relief, and ibuprofen cream was the second most likely.

For functional improvement, piroxicam was the most likely to be effective, followed by ibuprofen cream and diclofenac patch.

The risk of skin, gastrointestinal and cardiovascular AEs was not higher for topical NSAIDs overall compared to placebo. Only salicylate gel (odds ratio, 16.83) carried a significantly increased risk of withdrawal due to skin AEs.

“This is the first network meta-analysis to take into account all available evidence from randomized controlled trials directly or indirectly comparing topical NSAIDs in OA, thereby increasing the power of the study,” Dr. Zhang and colleagues write. “Further studies to examine the wear-off effect of topical NSAIDs for analgesia and functional improvement in OA are still warranted.”

Dr. Zhang was not available for an interview by press time.

Reference

  1. Zeng C, Wei J, Persson MSM, et al. Relative efficacy and safety of topical non-steroidal anti-inflammatory drugs for osteoarthritis: a systematic review and network meta-analysis of randomised controlled trials and observational studies. British Journal of Sports Medicine. 2018 Feb 7. [Epub ahead of print]

Share: 

Filed under:Drug UpdatesOsteoarthritis and Bone Disorders Tagged with:diclofenac patchosteoarthritis (OA)piroxicamtopical NSAIDs

Related Articles
    A Comprehensive Review of NSAID Cardiovascular Toxicity

    A Comprehensive Review of NSAID Cardiovascular Toxicity

    July 18, 2018

    Non-steroidal anti-inflammatory drugs (NSAIDs) are the most used drugs for acute and chronic pain. More than 30 billion doses of NSAIDs are consumed annually from more than 70 million prescriptions.1 Despite their common use, NSAIDs are not free of serious toxicities. In the pre-Vioxx (rofecoxib) era, gastrointestinal toxicity was the primary concern for many NSAIDs….

    Pulmonary Adverse Events with Low-Dose Methotrexate

    November 24, 2020

    In this large placebo-controlled trial, Sparks et al. examined the predictors and severity of pulmonary adverse events (AEs) in patients taking low-dose MTX. The researchers found that low-dose MTX increased the risk of pulmonary AEs, including possible pneumonitis.

    Immune-Related Adverse Events with Use of Checkpoint Inhibitors for Immunotherapy of Cancer

    March 29, 2017

    Introduction: Major advances in the past two decades have enhanced our understanding of the complex interactions between the immune system and cancer cells and their environment. Genetic and epigenetic alterations in tumor cells result in the expression of diverse antigens that can elicit an immune response, primarily mediated by T cells. Immune responses are regulated…

    Diclofenac May Boost MI Risk in Patients with Spondyloarthritis

    May 7, 2018

    NEW YORK (Reuters Health)—Risk of myocardial infarction (MI) is increased in patients with spondyloarthritis (SpA) who use the nonsteroidal anti-inflammatory drug (NSAID) diclofenac, but not in those who take naproxen, researchers say. Maureen Dubreuil, MD, MSc, of Boston University School of Medicine, and colleagues analyzed 20 years of medical records from the U.K.’s Health Improvement…

  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences